These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 18163425)

  • 1. The Glu228Ala polymorphism in the ligand binding domain of death receptor 4 is associated with increased risk for prostate cancer metastases.
    Langsenlehner T; Langsenlehner U; Renner W; Kapp KS; Krippl P; Hofmann G; Clar H; Pummer K; Mayer R
    Prostate; 2008 Feb; 68(3):264-8. PubMed ID: 18163425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A single nucleotide polymorphism in the extracellular domain of TRAIL receptor DR4 at nucleotide 626 in gastric cancer patients in Japan.
    Kuraoka K; Matsumura S; Sanada Y; Nakachi K; Imai K; Eguchi H; Matsusaki K; Oue N; Nakayama H; Yasui W
    Oncol Rep; 2005 Aug; 14(2):465-70. PubMed ID: 16012731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic polymorphism in EGF is associated with prostate cancer aggressiveness and progression-free interval in androgen blockade-treated patients.
    Teixeira AL; Ribeiro R; Cardoso D; Pinto D; Lobo F; Fraga A; Pina F; Calais-da-Silva F; Medeiros R
    Clin Cancer Res; 2008 Jun; 14(11):3367-71. PubMed ID: 18519765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic and plasma variation of insulin-like growth factor binding proteins in relation to prostate cancer incidence and survival.
    Johansson M; McKay JD; Rinaldi S; Wiklund F; Adami HO; Grönberg H; Kaaks R; Stattin P
    Prostate; 2009 Sep; 69(12):1281-91. PubMed ID: 19455605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of ACE I/D polymorphism on prostate cancer risk, tumor grade and metastatis.
    Yigit B; Bozkurt N; Narter F; Yilmaz H; Yucebas E; Isbir T
    Anticancer Res; 2007; 27(2):933-6. PubMed ID: 17465223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
    Okegawa T; Nutahara K; Higashihara E
    J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphisms in tumor necrosis factor-A gene and prostate cancer risk in North Indian cohort.
    Kesarwani P; Mandhani A; Mittal RD
    J Urol; 2009 Dec; 182(6):2938-43. PubMed ID: 19846139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients.
    Gupta A; Lotan Y; Ashfaq R; Roehrborn CG; Raj GV; Aragaki CC; Montorsi F; Shariat SF
    Eur Urol; 2009 May; 55(5):1124-33. PubMed ID: 18585843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of heterozygosity in chromosomal region 16q24.3 associated with progression of prostate cancer.
    Härkönen P; Kyllönen AP; Nordling S; Vihko P
    Prostate; 2005 Feb; 62(3):267-74. PubMed ID: 15389780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A polymorphism in the G protein beta3-subunit gene is associated with bone metastasis risk in breast cancer patients.
    Clar H; Langsenlehner U; Krippl P; Renner W; Leithner A; Gruber G; Hofmann G; Yazdani-Biuki B; Langsenlehner T; Windhager R
    Breast Cancer Res Treat; 2008 Oct; 111(3):449-52. PubMed ID: 17978878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pretreatment prostate-specific antigen velocity is associated with development of distant metastases and prostate cancer mortality in men treated with radiotherapy and androgen-deprivation therapy.
    Palma D; Tyldesley S; Pickles T;
    Cancer; 2008 May; 112(9):1941-8. PubMed ID: 18338814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel single nucleotide polymorphism of the cyclooxygenase-2 gene associated with breast cancer.
    Li F; Ren GS; Li HY; Wang XY; Chen L; Li J
    Clin Oncol (R Coll Radiol); 2009 May; 21(4):302-5. PubMed ID: 19138835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic variants in the death receptor 4 gene contribute to susceptibility to bladder cancer.
    Wang M; Wang M; Cheng G; Zhang Z; Fu G; Zhang Z
    Mutat Res; 2009 Feb; 661(1-2):85-92. PubMed ID: 19070628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The presence of the CYP11A1 (TTTTA)6 allele increases the risk of biochemical relapse in organ confined and low-grade prostate cancer.
    Celhar T; Gersak K; Ovcak Z; Sedmak B; Mlinaric-Rascan I
    Cancer Genet Cytogenet; 2008 Nov; 187(1):28-33. PubMed ID: 18992638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
    James ND; Caty A; Borre M; Zonnenberg BA; Beuzeboc P; Morris T; Phung D; Dawson NA
    Eur Urol; 2009 May; 55(5):1112-23. PubMed ID: 19042080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single nucleotide polymorphisms and haplotypes in the gene for vascular endothelial growth factor and risk of prostate cancer.
    Langsenlehner T; Langsenlehner U; Renner W; Krippl P; Mayer R; Wascher TC; Kapp KS
    Eur J Cancer; 2008 Jul; 44(11):1572-6. PubMed ID: 18514506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CDKN1B V109G polymorphism frequency and prostate cancer risk in Taiwan.
    Huang SP; Yu CC; Liu CC; Wu TT; Huang CH; Wu MT
    Urol Int; 2008; 81(1):36-40. PubMed ID: 18645269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association among polymorphisms in the steroid 5alpha-reductase type II (SRD5A2) gene, prostate cancer risk, and pathologic characteristics of prostate tumors in an Ecuadorian population.
    Paz-y-Miño C; Witte T; Robles P; Llumipanta W; Díaz M; Arévalo M
    Cancer Genet Cytogenet; 2009 Mar; 189(2):71-6. PubMed ID: 19215786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of clinical metastasis in prostate cancer patients receiving androgen deprivation therapy: results from CaPSURE.
    Abouassaly R; Paciorek A; Ryan CJ; Carroll PR; Klein EA
    Cancer; 2009 Oct; 115(19):4470-6. PubMed ID: 19637339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Manganese superoxide dismutase (MnSOD) genetic polymorphism is associated with risk of early-onset prostate cancer.
    Arsova-Sarafinovska Z; Matevska N; Petrovski D; Banev S; Dzikova S; Georgiev V; Sikole A; Sayal A; Aydin A; Suturkova L; Dimovski AJ
    Cell Biochem Funct; 2008 Oct; 26(7):771-7. PubMed ID: 18646267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.